Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18344466 | 1.00 | ALPI (0.43) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5066181 | 1.00 | ALPI (0.43) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL16932215 | 0.91 | MME (0.46) | PTGS1HTTALDH1A1LMNATSHR | |
| SCHEMBL16932216 | 0.91 | MME (0.46) | PTGS1HTTALDH1A1LMNATSHR | |
| Hydroxyamine SCHEMBL30526974 | 0.89 | MME (0.44) | PTGS1HTTCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL4234514 | 0.87 | ALOX5 (0.55) | PTGS1L3MBTL1 | |
| SCHEMBL2459695 | 0.86 | MME (0.45) | MEN1KMT2AALDH1A1LMNANPC1 | |
| SCHEMBL2102860 | 0.86 | MME (0.45) | MEN1KMT2AALDH1A1LMNANPC1 | |
| SCHEMBL5065736 | 0.86 | CYP2C9 (0.41) | PKMMEN1KMT2AHTTCYP1A2 | |
| SCHEMBL272595 | 0.86 | ALPI (0.46) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | UNIV AMIENS PICARDIE JULES VERNE (FR) | 2020-08-13 | — | — | US | disclosed |
| EP-3313840-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10294229-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180186799-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
| EP-3313840-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210034-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-2621508-B1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | SEATTLE GENETICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-8987209-B2 | N-carboxyalkyl-auristatin and the use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130261064-A1 | N-CARBOXYALKYL-AURISTATIN AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | QDPR, PNMT, CYP3A43 | ALPI 1956/4885PKM 106/4885PTGS1 596/4885 |
| US-10294229-B2 | Heteroaryl substituted aminopyridine compounds | IRAK4, IRAK3, IRAK2 | ALPI 3974/4885PKM 2837/4885PTGS1 1101/4885 |
| US-20130261064-A1 | N-CARBOXYALKYL-AURISTATIN AND THE USE THEREOF | HDGF, HGF, HGFAC | ALPI 2038/4885PKM 3711/4885PTGS1 2930/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | ALPI 1828/4885PKM 889/4885PTGS1 1835/4885 |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | HDGF, HGFAC, HGF | ALPI 1913/4885PKM 3323/4885PTGS1 2792/4885 |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | QDPR, PNMT, CYP3A43 | ALPI 3259/4885PKM 187/4885PTGS1 1196/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | ALPI 1828/4885PKM 889/4885PTGS1 1835/4885 |
| US-20180186799-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | IRAK4, IRAK3, IRAK2 | ALPI 3974/4885PKM 2837/4885PTGS1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.